Nebenwirkungen · Revestive
Revestive 5 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-215166 · Präparat HOS-155390
Adverse reactions are listed below by MedDRA system organ class and by frequency. Frequencies are defined as very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. All adverse reactions identified in post-marketing experience are italicised.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-23T08:51:00Z · SHA-256 ee78036578e80de286e3ba966c724bcc7d52c762c5f1b64fe55e22c6b675997f · Passage d9b63d4a423a6047ad6a20db166f422b93a52704c973a68de57539e802236a4b · Zeichen 1089–1567 im Abschnitt